Abstract：
Glucagon-like peptide-1 receptor (GLP-1R) agonists have garnered significant attention for their therapeutic potential in addressing the interconnected health challenges of diabetes, obesity, and cancer. The role of GLP-1R in type 2 diabetes mellitus (T2DM) is highlighted, emphasizing its pivotal contribution to glucose homeostasis, promoting β-cell proliferation, and facilitating insulin release. GLP-1R agonists have effectively managed obesity by reducing hunger, moderating food intake, and regulating body weight. Beyond diabetes and obesity, GLP-1R agonists exhibit a multifaceted impact on cancer progression across various malignancies. The mechanisms underlying these effects involve the modulation of signaling pathways associated with cell growth, survival, and metabolism. However, the current literature reveals a lack of in vivo studies on specific GLP-1R agonists such as semaglutide, necessitating further research to elucidate its precise mechanisms and effects, particularly in cancer. While other GLP-1R agonists have shown promising outcomes in mitigating cancer progression, the association between some GLP-1R agonists and an increased risk of cancer remains a topic requiring more profound investigation. This calls for more extensive research to unravel the intricate relationships between the GLP-1R agonist and different cancers, providing valuable insights for clinicians and researchers alike.
摘要：
胰高血糖素样肽-1受体（GLP-1R）激动剂在解决糖尿病相互关联的健康挑战方面的治疗潜力引起了人们的广泛关注。肥胖，和癌症。GLP-1R在2型糖尿病（T2DM）中的作用被强调，强调其对葡萄糖稳态的关键贡献，促进β细胞增殖，促进胰岛素释放。GLP-1R激动剂通过减少饥饿有效控制肥胖，节制食物摄入,调节体重。除了糖尿病和肥胖症,GLP-1R激动剂对各种恶性肿瘤的癌症进展表现出多方面的影响。这些效应的潜在机制涉及与细胞生长相关的信号通路的调节，生存,和新陈代谢。然而,目前的文献表明，缺乏对特异性GLP-1R激动剂如斯马鲁肽的体内研究，需要进一步研究以阐明其确切的机制和效果，特别是在癌症中。虽然其他GLP-1R激动剂在减轻癌症进展方面显示出有希望的结果，某些GLP-1R激动剂与癌症风险增加之间的关联仍然是一个需要更深入研究的话题.这需要更广泛的研究来解开GLP-1R激动剂与不同癌症之间的复杂关系。为临床医生和研究人员提供有价值的见解。
